Medical Devices industry cross border deals total $2.8bn globally in January 2022

Total medical devices industry cross border deals worth $2.8bn were announced globally for January 2022, with Ardian Holding $1.26bn private equity deal for 70% stake in Biofarma being the sector’s biggest investment, according to GlobalData’s deals database.

The value marked an increase of 18.4% over the previous month of $2.39bn and a drop of 58.8% when compared with the last 12-month average of $6.86bn.

In terms of number of cross border deals, the sector saw a rise of 17.86% with 66 deals in January 2022 when compared to the last 12-month average of 56 deals.

In value terms, Europe led the activity with cross border deals worth $1.66bn in January 2022.

medical devices industry cross border deals in January 2022: Top deals

The top five cross border deals accounted for 71.9% of the overall value during January 2022.

The combined value of the top five cross border deals stood at $2.03bn, against the overall value of $2.8bn recorded for the month.

The top five medical devices industry cross border deals of January 2022 tracked by GlobalData were:

1) Ardian Holding $1.26bn private equity deal for 70% stake in Biofarma

2) The $450m acquisition of Triad Life Sciences by ConvaTec Group

3) Smith & Nephew International $135m acquisition deal with Engage Surgical

4) The $100m venture financing of VIRTUE Diagnostics (Suzhou) by Lilly Asia ventures,Morningside Ventures,Oriza Holdings,PerkinElmer Ventures and Sequoia China Investment Management

5) Caesarea Medical Electronics,Clal Insurance Enterprises Holdings,Department of Defence – United States,European Commission,Horizons Ventures,La Maison Partners,Phoenix Insurance,Poalim Equity,Shavit Capital Fund,Social Capital,Touchwood Capital,Union Tech Ventures and Western Technology Investment $93m venture financing deal with MeMed Diagnostics